Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID R ERB

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1952366478
CMS profile
89023
Location
SPARTANBURG, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,466.10

140 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,436.96 138
Education $29.14 2

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID R ERB

NPI 1952366478 · CMS profile ID 89023

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

SPARTANBURG, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952366478?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID R ERB, NPI 1952366478, CMS profile ID 89023. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952366478?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DAVID R ERB, NPI 1952366478, CMS profile ID 89023. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952366478?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DAVID R ERB, NPI 1952366478, CMS profile ID 89023, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–140 of 140 matching records. This page contains 40 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1952366478?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

140 matching records · $2,466.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 140 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–140 of 140.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Grifols USA, LLC $18.7503/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918710587 CMS
AstraZeneca Pharmaceuticals LP $13.1703/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920247069 CMS
Insmed, Inc. $15.5703/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 906438139 CMS
Electromed, Inc. $18.3303/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948225135 CMS
Actelion Pharmaceuticals US, Inc. $94.1103/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885414705 CMS
Gilead Sciences, Inc. $19.4403/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929524441 CMS
GlaxoSmithKline, LLC. $11.5003/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945044959 CMS
Mylan Specialty L.P. $23.0603/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963898709 CMS
GENZYME CORPORATION $13.8703/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938761531 CMS
Philips Electronics North America Corporation $2.5603/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039224245 CMS
Philips Electronics North America Corporation $0.4903/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039224247 CMS
AstraZeneca Pharmaceuticals LP $16.8203/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920262411 CMS
Electromed, Inc. $3.6903/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948225131 CMS
Novartis Pharmaceuticals Corporation $16.2203/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893620523 CMS
Gilead Sciences, Inc. $34.9702/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929524447 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.8602/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955632635 CMS
AstraZeneca Pharmaceuticals LP $12.5802/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920262037 CMS
GENZYME CORPORATION $16.8502/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938761529 CMS
GlaxoSmithKline, LLC. $9.5602/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945044965 CMS
Grifols USA, LLC $18.1202/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918719169 CMS
GENZYME CORPORATION $17.9902/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938761517 CMS
Mylan Specialty L.P. $12.7602/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963893881 CMS
Actelion Pharmaceuticals US, Inc. $19.5502/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885414715 CMS
Amgen Inc. $12.8602/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939357479 CMS
AstraZeneca Pharmaceuticals LP $12.8602/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920229255 CMS
AstraZeneca Pharmaceuticals LP $12.5802/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920252979 CMS
Philips Electronics North America Corporation $5.1001/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039224251 CMS
Electromed, Inc. $20.8701/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948225127 CMS
GENZYME CORPORATION $14.9901/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938761511 CMS
Philips Electronics North America Corporation $35.2101/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039224249 CMS
Philips Electronics North America Corporation $85.4701/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039224257 CMS
Philips Electronics North America Corporation $85.4701/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039224259 CMS
Philips Electronics North America Corporation $11.4101/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039224253 CMS
Philips Electronics North America Corporation $11.4101/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039224255 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.5501/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955632633 CMS
AstraZeneca Pharmaceuticals LP $13.5701/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920261933 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.0201/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887361511 CMS
Electromed, Inc. $20.8701/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948225123 CMS
Gilead Sciences, Inc. $16.6601/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929524433 CMS
AstraZeneca Pharmaceuticals LP $122.5301/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920234167 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,227.02 144
PY2020 $1,292.39 84
PY2021 $2,239.15 143
PY2022 $2,466.10 140
PY2023 $3,397.99 63
PY2024 $227.14 11
PY2025 $224.49 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,466,754.37 509
PY2024 Principal investigator $2,201,737.32 367
PY2023 Recipient $9,825.26 7
PY2023 Principal investigator $1,674,628.38 1,560
PY2022 Recipient $1,722.00 1
PY2022 Principal investigator $1,047,846.77 797
PY2021 Recipient $4,604.87 2
PY2021 Principal investigator $405,371.19 20
PY2020 Recipient $69,718.60 2
PY2020 Principal investigator $491,750.29 44
PY2019 Principal investigator $190,896.99 50

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

509 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Currax Pharmaceuticals LLC $6,970.32 12/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718368
Principal investigator 1 Seqirus USA Inc $1,089.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185272402
Principal investigator 1 Seqirus USA Inc $1,089.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273776
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279499
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279501
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279503
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279505
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279507
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279509
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279911
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279913
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279915
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279917
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279919
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279921
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279923
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280065
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280067
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280753
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280755
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280793
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280795
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280797
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280799
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280801
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281233
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281235
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281237
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281239
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281241
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281243
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281245
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281247
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281249
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281251
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281253
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281255
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281257
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281259
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281485
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281489
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281491
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281493
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281495
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281497
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281499
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281501
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281503
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281505
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281507
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281509
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281511
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281513
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281515
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281517
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281519
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281521
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281523
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281525
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281527
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281529
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281531
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281533
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281535
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281537
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281539
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281541
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281543
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281545
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281547
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281549
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281551
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281553
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281555
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281557
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281559
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281561
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281563
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281565
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281567
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281569
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281571
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281573
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281575
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281577
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281579
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281581
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281583
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281585
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281587
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281589
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281591
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281593
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281595
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281597
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281600
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281603
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281605
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281607
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281609
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281611
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281613
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281615
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281617
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281619
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281621
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281623
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281625
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281627
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281629
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281631
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281633
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281635
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281637
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281639
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282131
Principal investigator 1 Verona Pharma, Inc. $9,804.98 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891949
Principal investigator 1 Verona Pharma, Inc. $1,000.00 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891993
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273802
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273805
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273807
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273810
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273812
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273814
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273816
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273818
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273820
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273822
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273824
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273826
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273828
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273830
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273833
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273836
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273838
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273840
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273842
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273844
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273846
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273848
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273850
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273852
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273854
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273856
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273858
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273860
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273862
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273864
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273866
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273868
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273870
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273872
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273874
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273876
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273878
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273880
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273882
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273884
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273886
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273888
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273890
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273892
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273894
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273896
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273898
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273900
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273902
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273904
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273906
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273908
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273910
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273912
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273914
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273916
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273954
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273956
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273958
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273960
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273962
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273964
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273966
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273968
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274042
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274044
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274046
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274048
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274050
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274052
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274054
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274056
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274058
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274060
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274062
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274064
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274066
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274068
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274070
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274072
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274074
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274076
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274162
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274164
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274166
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274168
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274170
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274172
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274174
Principal investigator 1 Seqirus USA Inc $1,019.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274300
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 12/17/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763779
Principal investigator 1 ModernaTX, Inc. $13,023.86 12/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002223
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,008.20 12/15/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800232
Principal investigator 1 ModernaTX, Inc. $1,444.00 12/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012392
Principal investigator 1 ModernaTX, Inc. $425.00 12/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012402
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 12/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683925
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683927
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683929
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683931
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683933
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683935
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683937
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683939
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683941
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683943
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683945
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 12/01/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763769
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763771
Principal investigator 1 Boehringer Ingelheim International GmbH $129.00 12/01/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763773
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $34,001.00 12/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220800842
Principal investigator 1 Seqirus USA Inc $1,709.60 11/21/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809811
Principal investigator 1 Seqirus USA Inc $469.80 11/21/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809816
Principal investigator 1 Currax Pharmaceuticals LLC $650.00 11/20/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718292
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 11/19/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763777
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $11,684.68 11/19/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998145
Principal investigator 1 Verona Pharma, Inc. $36,288.78 11/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891947
Principal investigator 1 Verona Pharma, Inc. $4,314.00 11/14/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891921
Principal investigator 1 Currax Pharmaceuticals LLC $6,840.95 11/13/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718248
Principal investigator 1 Verona Pharma, Inc. $500.00 11/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232892007
Principal investigator 1 Seqirus USA Inc $3,846.60 11/07/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809747
Principal investigator 1 Seqirus USA Inc $1,057.05 11/07/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809753
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683905
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683907
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683909
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683911
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683913
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683915
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683917
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683919
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683921
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683923
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763767
Principal investigator 1 Currax Pharmaceuticals LLC $1,300.00 10/30/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718188
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 10/27/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763775
Principal investigator 1 Verona Pharma, Inc. $2,525.58 10/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232892005
Principal investigator 1 Currax Pharmaceuticals LLC $6,969.97 10/14/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718114
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 10/10/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998143
Principal investigator 1 Verona Pharma, Inc. $35,809.63 10/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891945
Principal investigator 1 PFIZER INC. $1,500.00 10/09/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1228738097
Principal investigator 1 GlaxoSmithKline, LLC. $7,500.00 10/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192159862
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 10/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683883
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683885
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683887
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683889
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683891
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683893
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683895
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683897
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683899
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683901
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683903
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763765
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 09/24/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683873
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 09/24/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683875
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 09/24/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683877
Principal investigator 1 Boehringer Ingelheim International GmbH $15.66 09/24/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683879
Principal investigator 1 Boehringer Ingelheim International GmbH $19.32 09/24/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683881
Principal investigator 1 Boehringer Ingelheim International GmbH $459.54 09/24/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763763
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/22/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220801128
Principal investigator 1 Seqirus USA Inc $1,183.50 09/22/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276680
Principal investigator 1 Seqirus USA Inc $111.30 09/22/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276794
Principal investigator 1 Seqirus USA Inc $177.19 09/22/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276798
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,809.60 09/18/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800230
Principal investigator 1 Verona Pharma, Inc. $1,500.00 09/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232892110
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,500.00 09/11/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220800840
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 09/10/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998141
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683827
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683829
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683831
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683833
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683835
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683837
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683839
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683841
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683843
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683867
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763755
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,400.00 09/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800228
Principal investigator 1 ModernaTX, Inc. $93.96 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002193
Principal investigator 1 ModernaTX, Inc. $540.00 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002205
Principal investigator 1 ModernaTX, Inc. $200.00 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002207
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 08/26/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683869
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 08/26/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683871
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 08/26/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763761
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 08/21/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998137
Principal investigator 1 Genentech, Inc. $5,000.00 08/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211682234
Principal investigator 1 Verona Pharma, Inc. $2,400.00 08/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891865
Principal investigator 1 Verona Pharma, Inc. $10,000.00 08/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232892138
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,199.90 08/06/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800226
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 08/05/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998139
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683809
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683811
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683813
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683815
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683817
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683819
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683821
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683823
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683825
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683865
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763753
Principal investigator 1 Seqirus USA Inc $2,000.00 08/01/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276876
Principal investigator 1 Seqirus USA Inc $14,500.00 08/01/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276882
Principal investigator 1 Seqirus USA Inc $27,126.40 08/01/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276890
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,917.00 07/31/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800224
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 07/28/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763757
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 07/28/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763759
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 07/25/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220813637
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 07/22/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998135
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,672.70 07/22/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800222
Principal investigator 1 ModernaTX, Inc. $8,960.00 07/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012398
Principal investigator 1 Genentech, Inc. $5,110.00 07/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211682232
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,880.00 07/09/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800218
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,800.00 07/09/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800220
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683845
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683847
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683849
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683851
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683853
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683855
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683857
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683859
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683861
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683863
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763751
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 06/24/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683793
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 06/24/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683795
Principal investigator 1 Currax Pharmaceuticals LLC $12,839.16 06/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717974
Principal investigator 1 ModernaTX, Inc. $15,200.00 06/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012394
Principal investigator 1 Currax Pharmaceuticals LLC $2,275.00 06/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717661
Principal investigator 1 ModernaTX, Inc. $17,850.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012396
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683773
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683775
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683777
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683779
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683781
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683783
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683785
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683787
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683789
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683791
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763743
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763745
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763747
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research-Gaffney
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220763749
Principal investigator 1 Currax Pharmaceuticals LLC $7,386.60 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717904
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 05/27/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683801
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 05/27/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683803
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 05/27/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683805
Principal investigator 1 Boehringer Ingelheim International GmbH $11.04 05/27/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683807
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,400.00 05/27/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800214
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,125.00 05/27/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800216
Principal investigator 1 ModernaTX, Inc. $152,000.00 05/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012384
Principal investigator 1 ModernaTX, Inc. $264.93 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002191
Principal investigator 1 ModernaTX, Inc. $67.00 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002195
Principal investigator 1 ModernaTX, Inc. $165.64 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002201
Principal investigator 1 ModernaTX, Inc. $1,057.68 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002209
Principal investigator 1 ModernaTX, Inc. $291.83 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002213
Principal investigator 1 ModernaTX, Inc. $925.86 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002215
Principal investigator 1 ModernaTX, Inc. $6,044.48 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002217
Principal investigator 1 ModernaTX, Inc. $7,318.68 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002219
Principal investigator 1 ModernaTX, Inc. $5,750.92 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002225
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,000.00 05/15/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800212
Principal investigator 1 AstraZeneca Pharmaceuticals LP $64,880.42 05/09/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1185540591
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,949.30 05/09/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800210
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683751
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 05/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683753
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683755
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683757
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683759
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683761
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683763
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683765
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683767
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683769
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683771
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 05/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800206
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 05/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800208
Principal investigator 1 ModernaTX, Inc. $1,520.00 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012388
Principal investigator 1 Currax Pharmaceuticals LLC $697.13 04/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717789
Principal investigator 1 Genentech, Inc. $3,200.00 04/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211682208
Principal investigator 1 Genentech, Inc. $1,022.00 04/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211682212
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 04/23/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683797
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 04/23/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683799
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683731
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683733
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683735
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683737
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683739
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683741
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683743
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683745
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683747
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683749
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,665.40 03/26/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800204
Principal investigator 1 Currax Pharmaceuticals LLC $325.00 03/20/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717259
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,865.00 03/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185540589
Principal investigator 1 Currax Pharmaceuticals LLC $17,887.99 03/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717529
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683703
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683705
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683707
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683709
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683711
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683713
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683715
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683717
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683719
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683721
Principal investigator 1 ModernaTX, Inc. $1,002.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012390
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 02/25/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683727
Principal investigator 1 Genentech, Inc. $3,066.00 02/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211682200
Principal investigator 1 ModernaTX, Inc. $600.00 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002197
Principal investigator 1 ModernaTX, Inc. $800.00 02/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002211
Principal investigator 1 Currax Pharmaceuticals LLC $240.50 02/06/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717223
Principal investigator 1 Genentech, Inc. $5,244.00 02/06/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211682198
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683681
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683683
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683685
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683687
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683689
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683691
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683693
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683695
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683697
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683699
Principal investigator 1 Boehringer Ingelheim International GmbH $64.50 02/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683701
Principal investigator 1 Currax Pharmaceuticals LLC $481.00 01/30/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717193
Principal investigator 1 AstraZeneca Pharmaceuticals LP $70,392.76 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185540587
Principal investigator 1 ModernaTX, Inc. $33,069.86 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002203
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,000.00 01/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800202
Principal investigator 1 Eli Lilly and Company $1,892.00 01/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187891008
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 01/27/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683723
Principal investigator 1 Boehringer Ingelheim International GmbH $12.18 01/27/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683725
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,251.80 01/27/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800200
Principal investigator 1 ModernaTX, Inc. $5,225.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012386
Principal investigator 1 ModernaTX, Inc. $334.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253012400
Principal investigator 1 AstraZeneca Pharmaceuticals LP $37,633.60 01/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomised Placebo-Controlled Double-Blind Multi-Centre 4-week 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide Glycopyrronium and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1185540595
Principal investigator 1 ModernaTX, Inc. $4,800.00 01/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002199
Principal investigator 1 ModernaTX, Inc. $3,600.00 01/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1253002221
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,833.50 01/21/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800198
Principal investigator 1 AstraZeneca Pharmaceuticals LP $40,123.80 01/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) No dispute reported 06/30/2026 1185540593
Principal investigator 1 Seqirus USA Inc $506.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277187
Principal investigator 1 Seqirus USA Inc $506.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277189
Principal investigator 1 Seqirus USA Inc $506.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277191
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277193
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277195
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277197
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277199
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277201
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277203
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277205
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277207
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277507
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277509
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277511
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277513
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277515
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277517
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277519
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277521
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277523
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277525
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277527
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277529
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277531
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277533
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277535
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277537
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277539
Principal investigator 1 Seqirus USA Inc $1,088.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277541
Principal investigator 1 Seqirus USA Inc $506.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277565
Principal investigator 1 Seqirus USA Inc $506.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277567
Principal investigator 1 Seqirus USA Inc $506.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277569
Principal investigator 1 Seqirus USA Inc $506.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277571
Principal investigator 1 Seqirus USA Inc $506.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277573
Principal investigator 1 Seqirus USA Inc $506.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277575
Principal investigator 1 Seqirus USA Inc $506.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277577
Principal investigator 1 Seqirus USA Inc $506.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277579
Principal investigator 1 Seqirus USA Inc $506.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277581
Principal investigator 1 Seqirus USA Inc $506.00 01/08/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185277583
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $90.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800196
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683663
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683665
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683667
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683669
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683671
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683673
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683675
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683677
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683679
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Vitalink Research-Gaffney
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220683729